Associations of pretreatment neutrophil-to-lymphocyte ratio and thyroid-related immune-related adverse events with clinical outcomes in advanced upper gastrointestinal malignancies treated with immunotherapy: a retrospective cohort study

Cancer treatment has entered a new era where the body's own defense system is trained to fight tumors. This approach, known as immunotherapy, uses drugs called immune checkpoint inhibitors to release the brakes on the immune system, allowing it to recognize and attack cancer cells. While this strategy has transformed care for many patients with advanced cancers of the upper digestive tract—such as the esophagus, stomach, and the area where they meet—it does not work for everyone. Some people experience dramatic shrinkage of their tumors and long periods of stability, while others see their disease progress quickly. Because these outcomes vary so widely, doctors are searching for simple, accessible clues that can help predict who will benefit most before treatment even begins. Two such clues have recently come under scrutiny: a routine blood test that measures the balance of infection-fighting cells, and the appearance of specific side effects that signal the immune system is active.

Researchers at the First Affiliated Hospital of Xinjiang Medical University set out to investigate how these two factors relate to the success of immunotherapy in patients with advanced upper gastrointestinal malignancies. They looked back at the medical records of 102 patients who received this treatment between 2019 and 2024. The team focused on a number derived from a standard blood test called the neutrophil-to-lymphocyte ratio. Neutrophils are white blood cells that respond to inflammation and infection, while lymphocytes are the soldiers of the adaptive immune system that hunt down specific threats. A high ratio suggests a body dominated by general inflammation, which can sometimes suppress the immune system's ability to fight cancer. A low ratio suggests a more balanced state. The researchers also tracked whether patients developed thyroid-related immune-related adverse events. These are side effects where the immune system, once activated by the drug, mistakenly attacks the thyroid gland, causing it to become overactive or underactive. The study aimed to see if the starting blood ratio and the occurrence of these thyroid issues could predict how long patients would remain free from disease progression.

The analysis began by establishing a clear dividing line for the blood test results. Using a statistical method to find the best threshold for predicting outcomes, the team determined that a ratio of 2.44 was the critical point. Patients were then split into two groups: those with a ratio at or below 2.44, and those with a ratio higher than that. The results revealed a stark difference in how these groups responded to treatment. Those with the lower ratio saw a much higher rate of tumor shrinkage and disease control. Specifically, nearly 30 percent of the low-ratio group achieved a significant response to the therapy, compared to only about 5 percent of the high-ratio group. Furthermore, the disease was kept under control in roughly two-thirds of the low-ratio patients, whereas only about a quarter of the high-ratio patients saw their disease stabilized. This suggests that a lower level of background inflammation before treatment starts is linked to a much better chance of the therapy working.

The study also examined the thyroid side effects. It turned out that patients who developed thyroid issues during treatment had significantly better outcomes than those who did not. More than a third of the patients who experienced thyroid problems saw their tumors shrink, compared to fewer than 7 percent of those who did not. When the researchers combined these two pieces of information, a clear pattern emerged. The most favorable outcome was seen in patients who started with a low inflammation ratio and went on to develop thyroid side effects. These individuals had the longest periods of time without their cancer progressing. Conversely, the poorest outcomes were observed in patients who started with a high inflammation ratio and never developed thyroid issues. While the study did not find a definitive mathematical interaction proving that one factor changes the effect of the other, the combination of a calm starting immune state and an active immune response during treatment clearly identified the group with the best survival prospects.

To understand the strength of these findings, the researchers used advanced statistical models to account for other factors that could influence the results, such as whether the cancer had spread to the liver or the levels of certain tumor markers in the blood. Even after adjusting for these variables, the high inflammation ratio remained a strong predictor of shorter time without disease progression, while the development of thyroid side effects remained a strong predictor of longer survival. The data indicates that a high starting ratio is associated with a nearly double the risk of the disease progressing or the patient dying compared to a low ratio. Similarly, the presence of thyroid side effects was associated with a significantly lower risk of these negative outcomes. The researchers noted that the high-ratio group tended to have more liver metastases and higher levels of tumor markers, which are signs of more aggressive disease, but the blood ratio itself provided unique information that these other factors did not fully explain.

This work offers a practical way to look at patient outcomes using tools that are already available in almost every clinic. The blood test used to calculate the ratio is inexpensive, routine, and performed before treatment begins, making it a useful tool for early risk assessment. The monitoring of thyroid function is also standard practice during immunotherapy, meaning the information about side effects is gathered as part of normal care. By looking at both the starting condition and the body's reaction during treatment, doctors can get a clearer picture of how a patient is likely to fare. However, the authors are careful to note that this study was conducted at a single hospital with a relatively small number of patients. The specific cutoff value for the blood test was derived from this group and has not yet been confirmed in other populations. Therefore, while the results are promising and suggest a clear link between inflammation, immune activation, and treatment success, they should be viewed as an important step that requires further confirmation in larger, broader studies before becoming a standard rule for clinical decision-making.